Importantly, TMEM219 agonists may represent a novel therapy for tumors with significantly lower expression of IGFBP-3 but not TMEM219 compared to the counterpart normal tissues, such as breast invasive carcinoma, uterine corpus endometrial carcinoma, liver hepatocellular carcinoma, and prostate adenocarcinoma. The gene discussed is TMEM219; the disease is uterine corpus endometrial carcinoma.